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Abstract
Background: Venous leg ulceration is a common and costly problem that is expected to worsen as the population
ages. Current treatment is compression therapy; however, up to 50 % of ulcers remain unhealed after 2 years, and
ulcer recurrence is common. New treatments are needed to address those wounds that are more challenging to
heal. Targeting the inflammatory processes present in venous ulcers is a possible strategy. Limited evidence suggests
that a daily dose of aspirin may be an effective adjunct to aid ulcer healing and reduce recurrence. The Aspirin in
Venous Leg Ulcer study (ASPiVLU) will investigate whether 300-mg oral doses of aspirin improve time to healing.
Methods/design: This randomised, double-blinded, multicentre, placebo-controlled, clinical trial will recruit participants
with venous leg ulcers from community settings and hospital outpatient wound clinics across Australia. Two hundred
sixty-eight participants with venous leg ulcers will be randomised to receive either aspirin or placebo, in addition to
compression therapy, for 24 weeks. The primary outcome is time to healing within 12 weeks. Secondary outcomes are
ulcer recurrence, wound pain, quality of life and wellbeing, adherence to study medication, adherence to compression
therapy, serum inflammatory markers, hospitalisations, and adverse events at 24 weeks.
Discussion: The ASPiVLU trial will investigate the efficacy and safety of aspirin as an adjunct to compression therapy to
treat venous leg ulcers. Study completion is anticipated to occur in December 2018.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12614000293662
Keywords: Aspirin, Venous leg ulcers, Compression, Healing
Background
Venous leg ulcers (VLUs) are a common and costly
problem, usually managed in general practice and com-
munity settings with variability in clinical practice [1].
Age-related venous leg ulceration is the most common
cause of lower limb ulceration in developed countries,
with an overall prevalence between 1.65 and 1.74 % and
substantially higher rates in adults of age 65 and older
[2]. These ulcers become chronic due to the underlying
pathophysiology and are associated with pain and heavy
exudate [3]. In 2010, an estimated 400,000 Australians
were treated for VLUs, translating into costs of more
than AU$3 billion per year [4]. People with chronic ven-
ous insufficiency (CVI) are prone to developing VLUs
on the lower legs, which can occur spontaneously or
after minor trauma [5]. Up to 70 % of VLUs will heal
within 12 weeks if adequate compression is applied and
patients adhere to compression treatment [6]. People
with VLUs also often suffer from diabetes and obesity,
further impacting the healing [7]. The natural history of
ulceration is a cycle of healing and recurrence, which
has considerable impact on an individual’s health, quality
of life, and socioeconomic costs [8, 9]. Increasing life
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expectancy means that more people will be living with
VLUs in the future, increasing the financial and health-
care burden of this already costly chronic disease [10, 11].
Current treatment of venous leg ulcers
Best practice VLU treatment is a firm graduated com-
pression bandage to aid venous return [12]. This assists
by reducing venous hypertension, enhancing venous re-
turn, and reducing peripheral oedema. Data shows that
VLUs heal more quickly with compression than without
[12]. Treatment inconsistencies regarding the bandage
application and limited patient adherence to compres-
sion therapy have been identified as limiting factors to
healing [1]. Many healed ulcers recur within 3 months
of healing, possibly due to a prolonged inflammatory
response [6]. Aspirin is a widely used and relatively well-
tolerated drug. It has the potential to reduce inflamma-
tion via generalised COX inhibition.
Classical signs of inflammation have been observed in
biopsies and plasma samples in experimental models of
venous disease [13], and evidence supports the hypoth-
esis that, in humans, chronic venous disease is associ-
ated with the inflammatory cascade [14]. The cascade
begins with increased vascular permeability and pro-
gresses to the adhesion of leukocytes and platelets to the
endothelium. Over time, increased cell apoptosis, deg-
radation of the basement membrane and extracellular
matrix proteins, and vascular restructuring of the venous
varicosities occurs [15]. High-level evidence shows larger
wounds of longer duration (>10 cm2 and > 12 months
old) at the first visit have only a 20 % chance of healing
by the 24th week of care, whereas a wound that is
smaller than 10 cm2 and has been present for less than
12 months has a better (70 %) chance of healing by
24 weeks [10, 16]. A perpetual inflammatory state may
contribute to difficult-to-heal chronic wounds [17].
VLUs may achieve better healing and be less likely to
occur due to anti-inflammatory effects if the compres-
sion bandage is used concomitantly with aspirin [18].
Aspirin as a novel treatment in VLUs
Aspirin has several actions potentially capable of influ-
encing the progression of VLUs through the suppression
of inflammation. It inhibits the enzyme cyclooxygenase
(COX), thereby blocking the synthesis of several potent
stimulators of inflammation [19]. In vivo studies suggest
that 300 mg aspirin suppresses inflammatory markers
and may promote ulcer healing [20]. Aspirin also re-
duces prostaglandin-2 and thromboxane A2, which are
involved in platelet aggregation [19]. The production
of these compounds underpins part of the anti-
inflammatory effect of aspirin, along with the poten-
tial to inhibit both leukocyte activation and platelet
function [18]. The effect of low-dose aspirin on serum
levels of inflammatory cytokines, such as interleukin 6
(IL-6) and tumour necrosis factor-alpha (TNF-a), is not
entirely clear at present. In one study of aspirin in people
with VLUs, investigators reported increased fibrinogen
and an increased coagulation rate, which increased the
healing rates [21]. Some publications report little or no ef-
fect on the serum levels of pro-inflammatory cytokines,
while others show reduced serum IL-6 and TNF-a with
2 weeks treatment using 300 mg/day aspirin [20].
Previous studies of aspirin in venous leg ulcers
Two small, randomised, controlled trials (RCTs) suggest
aspirin may be effective in speeding ulcer healing and
may reduce the ulcer recurrence, although the quality of
this evidence is low. An RCT conducted in the United
Kingdom [21] (n = 20) reported that daily oral adminis-
tration of aspirin (300 mg) with compression decreased
the time to ulcer healing (p < 0.01) and the proportion of
participants healed when compared to placebo with
compression bandaging over a 4-month period. Thirty-
eight per cent of the aspirin participants reported
complete healing compared with 0 % in the placebo
group (p < 0.007). Improvement, assessed by a reduction
in wound size, occurred in 52 % of the aspirin group
compared with 26 % with placebo (p < 0.007). The po-
tential benefits of aspirin as an adjunct to compression
were identified, but the sample size was small, and the
mechanism by which aspirin improved healing or the ef-
fect on recurrence was not reported [20]. A more recent
Spanish RCT [22] (n = 51) compared daily administra-
tion of aspirin (300 mg) in addition to the use of a
compression bandage with compression alone over a
5-month period [22]. Little difference was observed in
the complete healing between the groups (21/28 aspirin
and 17/23 compression alone); however, the average time
to healing was shorter (12 weeks in the aspirin group ver-
sus 22 weeks in the compression-only group), and the
average time to recurrence was longer in the aspirin group
(39 days (SD 6.0) for aspirin versus 16.3 days (SD 7.5) for
compression alone). No information regarding the placebo
was reported.
The ASPiVLU study in Australia will investigate the
effects of aspirin in people with VLUs in a large, rando-
mised, double-blinded, placebo-controlled trial. We have
selected a daily dose of 300 mg aspirin, as current evi-
dence was derived from studies using this dose.
Study objectives
The primary objective is to determine whether daily
aspirin (300 mg) as an adjunct to compression improves
the time to healing of the target ulcer in a 12-week treat-
ment period.
The secondary objective is to determine the effects
of aspirin on ulcer recurrence, wound pain, quality
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of life and wellbeing, adherence to study medication,
adherence to compression therapy, serum inflamma-




ASPiVLU is a randomised, double-blinded, multicentre,
placebo-controlled, clinical trial to determine the clinical
effectiveness of aspirin as an adjunct to compression in
healing venous leg ulcers.
Study setting and participants
The study population consists of adult patients living in
Australia. The study is being conducted in four states
(Victoria, New South Wales, Queensland, and Tasmania).
Potential participants will be identified from community
nursing settings, general practice clinics, and hospital out-
patient wound clinics. All eligible patients will be identi-
fied at six participating ASPiVLU study wound clinics and
offered study participation.
Inclusion criteria
Inclusion criteria are as follows:
 Age 18 years and older
 Have one or more leg ulcers in the presence of
venous insufficiency confirmed by clinical assessment
and/or duplex ultrasound
 Target ulcer (largest ulcer if more than one) is
separated from the other ulcers by at least 1 cm
 Target ulcer present for at least 6 weeks or has prior
history of venous ulceration
 Target ulcer area ≥ 1 cm2 to ≤ 20 cm2 as measured
by digital planimetry techniques
 Ankle brachial pressure index (ABPI) measure
of ≥ 0.7 mmHg or systolic toe pressure ≥ 50 mmHg to
exclude arterial insufficiency
 Able to provide informed consent (decision made
according to the medical practitioner’s clinical
judgement)
Exclusion criteria
Exclusion criteria include the following:
 Current, daily aspirin use
 Aspirin intolerance
 Any existing condition or treatment that is a
contraindication to aspirin therapy or to participate
in the trial (decision made according to the medical
practitioner’s clinical judgement)
 Concurrent use of any other antiplatelet or
anticoagulation therapy
 Pregnancy or breastfeeding
Consent
Written information, in the form of a patient informa-
tion and consent form, will be provided after verbal
explanation of the research study. Patients will have the
opportunity to discuss participation with research staff
prior to enrolment. Written informed consent will be
obtained from each participant prior to randomisation.
Screening assessment
After giving consent, the patients will be screened at
wound clinics to verify eligibility. Eligibility will be con-
firmed by the wound clinic doctor. Prior to randomisation,
baseline data, including age, gender, smoking status, ethni-
city and employment status, medical history and current
medication use, will be recorded. A physical examination
by a wound clinic consultant will include an assessment of
the target ulcer, measurement of the wound surface area,
and digital photography of the wound.
Intervention
Study participants will be allocated to either active treat-
ment with aspirin at a dose of 300 mg daily or inactive
placebo. Study tablets are enteric-coated, un-scored,
white tablets with identical appearance, provided by
Bayer Pharma AG for the ASPiVLU trial. Participants
will be advised to take one tablet each morning approxi-
mately half an hour before other medications to avoid
potential drug interactions. Participants will continue to
take the study medication daily for 24 weeks, regardless
of whether or not the target ulcer heals.
Compression therapy
All participants will be treated with compression therapy
(the system of choice will be guided by clinician discre-
tion and patient preference) for 12 weeks or until
complete healing of the target ulcer occurs. Details of
the compression type will be noted in the case report
form. Once ulcer healing is achieved, the participants
will be fitted with below-knee compression stockings
that deliver between 23 mmHg to 32 mmHg compres-
sion at the ankle to prevent ulcer recurrence.
Randomisation
Patients will be randomly assigned to aspirin or placebo
via an electronic data capture system (EDC). The ran-
domisation list will be generated by an independent stat-
istician and implemented together with medication
number selection by the database programmer. Random-
isation codes will be allocated via a password-protected
system.
Allocation concealment and implementation
The study medication will be packaged in identical
containers. Each container will be pre-labelled (by an
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independent drug-packaging group contracted to pro-
vide the study medication) with a study identifier ac-
cording to the randomisation schedule. Allocation will
be stratified by wound clinic and wound size as mea-
sured by the Margolis index [10]. The Margolis index
is a prognostic score for venous ulcer healing derived
from dichotomous categorisations of the ulcer area
and duration of the current ulcer. Hence, stratifica-
tion aims to avoid baseline imbalances in the ulcer
size and duration, which are highly predictive of out-
come. Stratification based on clinic site will avoid
variance in any baseline characteristics related to the
geographical location or local clinical practice. The
study investigators and the research nurses distribut-
ing the medication and assessing outcomes will re-
main blind to the treatment allocation.
Un-blinding
Un-blinding will occur in the event of a clinical emer-
gency in which the knowledge of the medication taken is
essential for the participant’s clinical management. The
code can be broken by contacting the Trial Pharmacist
via the ASPiVLU Trial Centre. Reasons for un-blinding
will be recorded, and participants will be encouraged to
resume their assigned medication, if possible, after their
immediate condition has resolved.
Primary outcome measure
The primary outcome is the time to healing of the target
ulcer at 12 weeks after randomisation. Healing is defined
as 100 % epithelialisation, with no exudate or scab.
Proof of healing will be confirmed by an independent
expert review of the digital photos of the ulcer. Time
to healing will be measured in weeks from the date
of randomisation.
The target ulcer is defined as the largest ulcer at base-
line, which is separated from other ulcers by at least
1 cm and has a surface area between 1 cm2 and 20 cm2.
Secondary outcome measures
The following secondary outcomes will be assessed in all
participants at 24 weeks after randomisation.
Recurrence of target ulcer
Recurrence is defined as healed at 12 weeks and recur-
rence free at 24 weeks. After healing, the participants
will be followed up to assess target ulcer recurrence.
This will occur via monthly phone calls by the research
staff from the date of healing to 24 weeks from
randomisation.
Wound pain score
(Baseline and weekly until the wound is healed or to
12 weeks, whichever comes first, and then monthly via
phone call until the study completion at 24 weeks): The
participants’ self-reported assessments of pain associated
with their VLUs in the past week will be measured with
an 11-point (0–10) numerical rating scale, where a score
of ‘0’ represents no pain, and ‘10’ represents the max-
imal pain imaginable.
Health-related quality of life and wellbeing index
(Baseline, 12 weeks, and 24 weeks): The EQ-5D is a
health-related quality of life and wellbeing instrument.
The EQ-5D-5 L is a widely used generic preference-
based measure of health outcomes [23]. It consists of a
descriptive system together with a visual analogue 0–100
scale. It assesses five dimensions of health – mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression. Participants are asked to rate each dimen-
sion as one of five levels (no problems, slight problems,
moderate problems, severe problems, or extreme
problems). This can result in 3125 (55) possible health
states, which can be converted to health utilities using
nation-specific tariffs, which have been developed for a
number of countries [24].
Adherence to study medication
(Weekly from baseline until healed or to 12 weeks,
whichever comes first, and then monthly to 24 weeks
from randomisation): Participants will be asked to self-
report trial medication adherence and to present medi-
cation containers for pill counts at 24 weeks.
Adherence to compression treatment
(Weekly from baseline until healed or to 12 weeks,
whichever comes first, and then monthly to 24 weeks
from randomisation): Participants will be asked to report
whether they adhered to wearing the compression on a
categorical scale of ‘wear everyday’, ‘wear ≥ 3 days/week’,
‘wear ≤ 2 days per week’, and ‘do not wear’.
Adverse events
(Weekly until healed or to 12 weeks, whichever comes
first, and then monthly via phone call until the study
completion at 24 weeks): Adverse events will be elicited
by open-ended questions and recorded in the adverse
events log.
Hospitalisation
At each contact, participants will be asked to report
hospitalisation that occurs for any reason during the
24-week study period.
Serum inflammatory markers
(Baseline, 12 weeks, and 24 weeks): At these time points,
20 ml of blood will be collected from participants. Prior
to assay, the blood will be centrifuged as per standard
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operating procedures and frozen at −80 °C for storage.
Assays of inflammatory markers and cytokines will
assess interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12, IL-13; IFN-γ; TNF-α; and, possibly, MCP1; CRP;
and P-selectin (subject to costs).
A schematic of the ASPiVLU trial design is provided
in Fig. 1, and an overview of the study schedule is
provided in Table 1. The CONSORT flow diagram is
provided in Fig. 2.
Participation discontinuation
If a participant withdraws from the study, the reason will
be documented, and the participant will be referred for
routine care to the wound clinic, if required. Participants
will be asked to allow measurement of the target ulcer at
routine treatment visits for ascertainment of outcomes.
Participants unwilling to continue participation during
the follow-up period will be asked for permission to
allow investigators to collect information from their
medical records.
Follow-up of participants ‘off protocol’
‘Off protocol’ is defined as those study participants who
cease trial medications on clinical grounds or commence
on aspirin therapy for other reasons. This may be short-
term or for the remainder of the study. Regardless of the
decision to continue with study medication, these partic-
ipants will be asked to participate in all scheduled
follow-up contacts, as if they were maintaining full par-
ticipation. Those who are unwilling or unable to do this
will be asked to agree to phone call or mail follow-up,
and/or permission for study staff to continue surveil-
lance of their clinical records.
Sample size
We estimate that 268 participants will be required.
Based on a previous compression bandaging study, we
expect 50 % of ulcers to have healed at 12 weeks in the
placebo group [15]. Aspirin is expected to increase this
additively by 20 %; that is, we expect 70 % of the aspirin
group to be healed at 12 weeks [20, 22]. Twelve-week
survival rates of 0.5 and 0.3 in the placebo and aspirin
groups, respectively, translate to cumulative hazard rates
of 0.7 and 1.2, respectively, and a hazard ratio of 1.74.
For 90 % power to detect this hazard ratio in a two-
sided (alpha = 0.05) test for time to healing, analysed by
a log-rank test, we require 121 people per group. Allow-
ing for 10 % loss to follow-up, we will recruit n = 134
participants per group. With this sample size, and the
same assumptions about percentage healed, we have
87 % power for a two-sample test of the proportion
healed at 12 weeks.
For the secondary outcome of healed at 12 weeks and
recurrence free at 24 weeks, we anticipate 60/121
Screening of venous ulcer in participating wound clinics. 
Clinic research nurses will work with community nurses, 
practice nurses in GP clinics and hospital staff to identify 
eligible patients, screen and consent.
Informed consent to enter study and final eligibility 
assessment performed at wound clinic
Randomise to aspirin or placebo alongside usual care
Aspirin Placebo
Drug distributed from wound clinic following 
randomisation
Assessment/usual care by community nurse or GP clinic 
or wound clinic weekly
Research nurse in wound clinic will review impact of 
treatment every 4 weeks following randomisation 
Research nurse in wound clinic or treating nurse in 
community will:
Administer weekly usual care
Check medication adherence 
Check compression adherence
Assess and record impact of treatment (ulcer size, 
healing, pain)
Monitor adverse events/hospitalisations
Treatment to continue unt il healed or to 12 weeks, 
whichever comes first.
If healed at or prior to  12 weeks commence monthly 
phone follow up until end of study period (24 weeks).
If unhealed at 12 weeks continue with treatment as per 5 
points above until end of study period (24 weeks).
Fig. 1 Schematic of the Aspirin in Venous Leg Ulcer trial
(ASPiVLU) design
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Table 1 Study schedule
Measurement/activity Screeninga Treatment period in weeks Follow-up period
(Weekly wound management and assessments until target ulcer healed OR 12 weeks – whichever occurs first. The 12-week
visit is mandatory for all participants regardless of ulcer status.)








Recruitment & randomisation X
Target ulcer assessment – general features X X X X X X X X X X X X X3
Wound pain score X X X X X X X X X X X X X3 X X
Target ulcer assessment – size (tracing) &
photo
X X X X3
Medical history including demographics &
medications
X
Physical examination including vital signs X
QOL assessment (EQ-5D-5L) X X X
Serum sample X X X
Trial medication dispensed X
Ulcer care education X
Adherence to compression (or hosiery) X X X X X X X X X X X X X X
Adherence to trial medication X X X X X X X X X X X X X X
Concomitant/new medication X X X X X X X X X X X X X X
Adverse events including hospitalisation X X X X X X X X X X X X X X
Wound assessment X X X X X X X X X X X X
Ulcer prevention education X2 X2 X2 X2 X2 X2 X2 X2 X2 X2 X2 X
Target ulcer recurrence assessment X2 X2
Refer to wound clinic X3 X4 X4
Reconciliation of medication X
aScreening to be conducted within 14 days of baseline (day 1) assessment
bAssessment conducted only if the target ulcer unhealed
X2 = if healed
X3 = if not healed










(approximately 50 %) in the placebo group to be healed
at 12 weeks and 85/121 (approximately 70 %) in the as-
pirin group to be healed. Of these participants with
healed ulcers, in the placebo group, we expect 24 (40 %
of 60) to recur by 24 weeks from baseline, i.e. 36/121 to
be healed at 12 weeks and recurrence free at 24 weeks.
We have 90 % power to detect a difference between the
placebo and aspirin groups if the proportion healed at
12 weeks and recurrence free at 24 weeks in the aspirin
group is 51 % (n = 62) of 121 participants.
Data management and statistical analyses
Results from the trial assessments will be recorded in
the electronic case report forms (CRF) via an electronic
data capture (EDC) system. The REDCap EDC system is
a secure, web-based system that is available for free to
institutional partners (www.projectredcap.org). Each
clinical site will have a unique password and will enter
data directly into the EDC system via a tablet supplied
by the ASPiVLU trial.
The primary and secondary outcomes will be analysed
according to intention-to-treat principles, i.e. by the
treatment to which they were randomised. The primary
outcome will be analysed with a log-rank test to com-
pare the time to healing, up to the 12-week time point,
i.e. with censoring at 12 weeks, between the two rando-
mised treatment groups. A secondary analysis of the pri-
mary hypothesis will use logistic regression to compare
between groups the proportion of participants healed by
12 weeks. The secondary outcome, the proportion of pa-
tients healed by 12 weeks and remaining recurrence-free
at 24 weeks, will be compared between the two groups
using logistic regression. The levels of inflammatory
markers in the plasma will be compared between groups
using a linear mixed model with a random effect for par-





Assessed for eligibility (n =  )
Randomized (n =  )
Excluded  (n =   )
Not meeting inclusion criteria 
(n =  )
Declined to participate (n =  )
Other reasons (n =  )
Allocated to intervention (n =  )
Received allocated intervention (n =  )
Did not receive allocated intervention 
(give reasons) (n =  )
Allocated to placebo (n =  )
Received allocated placebo (n =  )
Did not receive allocated placebo (give 
reasons) (n =  )
Lost to follow-up (give reasons) (n =  )
Discontinued inte rvention (give 
reasons) (n =  )
Lost to follow-up (give reasons) (n =  )
Discontinued placebo (give reasons) 
(n =  )
Analysed  (n =  )
Excluded from analysis (give reasons) 
(n =  )
Analysed  (n = )
Excluded from analysis (give reasons) 
(n =  )
Fig. 2 The Aspirin in Venous Leg Ulcer (ASPiVLU) trial flow diagram
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repeat measures over time, adjustment for the bio-
marker’s level at randomisation, and an interaction
between the time since randomisation and the random-
isation group. The secondary outcomes of pain score
and EQ-5D-5L will be analysed in linear mixed models,
with a random effect for participant, an adjustment for
the measure at randomisation, and an interaction be-
tween the time since randomisation and the randomisa-
tion group.
A secondary set of analyses will be performed to adjust
for two predictors of healing: (1) ulcer area and ulcer
duration at baseline and (2) any baseline characteristics
that are found to be imbalanced between the groups
to the extent of a 0.25 standard deviation difference
in means (quantitative measures) or an odds ratio of
1.5 (binary measures). For time to healing these sec-
ondary analyses will use a Cox proportional hazards
regression.
Ethics approval
Full ethics approval has been granted from Alfred Health
(HREC/14/Alfred/2 (Project 146/14)), Monash University
(Project CF14/2106 - 2014001084), and Austin Health
(HREC/14/Alfred/2 Project/15/Austin/55). Recruitment
in any individual centre will not commence until local
approvals are obtained. The ASPiVLU study will be
conducted in accordance with the Declaration of
Helsinki 1964, as revised in Edinburgh in 2008, the
Good Clinical Practice Guide (CPMP/ICH/135/95)
and with the National Health and Medical Research
Council Guidelines on Human Experimentation.
Discussion
This protocol outlines the design of a randomised,
double-blinded, multicentre, placebo-controlled, clinical
trial of aspirin in the management of VLUs. ASPiVLU
will allow us to answer the question of whether daily
active treatment with 300 mg aspirin improves time to
healing of venous leg ulcers. The ASPiVLU sample will
be sourced from four states in Australia, thereby pro-
viding a broad range of representation from the com-
munity. We will provide data on the efficacy and
safety of aspirin in this population for a 24-week
study period. Low-dose aspirin therapy may improve
time to healing and decrease the number of recurrent
VLU episodes. If proved effective, the low cost of as-
pirin therapy as an adjunct to compression would
make it an affordable preventive agent for people with
VLUs in all countries.
Other ongoing aspirin studies
Two other randomised trials investigating aspirin in
people with venous leg ulcers are ongoing: the
AVURT (Aspirin for Venous Ulcers: Randomised Trial
NCT02333123) and the Aspirin4VLU (Low-Dose Aspirin
for Venous Leg Ulcers NTC 02158806). Chief investigators
of the currently recruiting aspirin RCTs have formed the
Aspirin for Venous Leg Ulcers Collaborative (AVLUC).
AVLUC will combine data from the ASPiVLU study and
the AVURTand Aspirin4VLU studies for individual patient
data (IPD) meta-analysis.
Current ASPiVLU study status
We have commenced recruitment at the Alfred, University
of Tasmania, Melbourne Health, and Austin sites. Site-
specific ethics approval from Prince Charles Hospital and
Western Sydney Local Health are in progress, and all
necessary ethical approvals for these participating sites will
be obtained prior to study recruitment.
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